Brief: Olix Pharmaceuticals Receives Regulatory Approval To Commence Phase 1 Clinical Trial Of Treatment Of Androgenic Alopecia
23/03/2023 12:53
March 23 (Reuters) - OliX Pharmaceuticals Inc
226950.KQ :
* OLIX PHARMACEUTICALS RECEIVES REGULATORY APPROVAL TO
COMMENCE
PHASE 1 CLINICAL TRIAL OF TREATMENT OF ANDROGENIC ALOPECIA
* OLIX PHARMACEUTICALS INC - PHASE 1 TRIAL OF OLX72021 HAS
BEEN
APPROVED FOR INITIATION IN AUSTRALIA
* OLIX PHARMACEUTICALS INC - WILL EVALUATE SAFETY AND
TOLERABILITY
OF OLX72021 IN PHASE 1 CLINICAL TRIAL
* OLIX PHARMACEUTICALS INC - ALSO PLANS TO DEVELOP OLX72021
AS A
COSMECEUTICAL FOR HAIR LOSS
Source text for Eikon: ID:nBw6Jls5ha
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment